Get the Stockscreener App
1.09
0.91%
-0.01
After Hours:
1.08
-0.01
-0.92%
Okyo Pharma Limited Stock (OKYO) Latest News
H.C. Wainwright maintains Buy on OKYO Pharma with $7 target - MSN
H.C. Wainwright maintains Buy on OKYO Pharma with $7 target By Investing.com - Investing.com South Africa
OKYO Pharma (NASDAQ:OKYO) Receives Buy Rating from HC Wainwright - Defense World
Yi Chen’s Buy Recommendation on OKYO Pharma: Promising Potential of OK-101 for Neuropathic Corneal Pain Amid Financial and Regulatory Challenges - TipRanks
OKYO Pharma Announces Chairman and CEO Acquire Shares -February 03, 2025 at 09:04 am EST - Marketscreener.com
OKYO Pharma Announces Chairman and CEO Acquire Shares -January 31, 2025 at 07:00 am EST - Marketscreener.com
OKYO Pharma has dry eyes as a lucrative prize in its sights - Proactive Investors UK
OKYO Pharma insiders buy shares amid clinical trials - MSN
OKYO Pharma insiders acquire shares - Proactive Investors USA
OKYO Pharma insiders buy shares amid clinical trials By Investing.com - Investing.com South Africa
OKYO Pharma poised for multi-billion-dollar opportunity in ocular treatment market, analysts believe - Proactive financial news
OKYO Pharma Executives Increase Shareholdings, Affirming Market Confidence - TipRanks
OKYO Pharma Announces Chairman and CEO Acquire Shares - The Manila Times
OKYO Pharma advances neuropathic corneal pain drug trial - MSN
OKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of Second Quarter - GlobeNewswire
OKYO Pharma Advances Clinical Trials with Encouraging Interim Results - TipRanks
OKYO Pharma advances neuropathic corneal pain drug trial By Investing.com - Investing.com Australia
OKYO Pharma nears full enrollment for neuropathic corneal pain trial with results expected by year-end - Proactive Investors UK
OKYO Pharma nears full enrollment for neuropathic corneal pain trial - Proactive Investors USA
MUSQ Global Music Industry ETF and OKYO Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire
OKYO Pharma secures $1.4 million in non-dilutive funding - MSN
OKYO Pharma secures $1.4 million non-dilutive funding - MSN
Okyo Pharma receives $1.4M in non-dilutive financing - Yahoo Finance
OKYO Pharma (NASDAQ:OKYO) Shares Down 0.4% – What’s Next? - Defense World
OKYO Pharma secures $1.4 million non-dilutive funding By Investing.com - Investing.com Australia
OKYO Pharma secures non-dilutive funding to advance clinical programs - Proactive Investors USA
OKYO Pharma receives $1.4 million in non-dilutive funding, stock up - MSN
OKYO Pharma Secures $1.4 Million to Boost Ophthalmic Innovations - TipRanks
OKYO Pharma Receives $1.4 Million in Non-Dilutive Funding - The Manila Times
OKYO Pharma secures $1.4 million in non-dilutive funding By Investing.com - Investing.com South Africa
OKYO Pharma Secures $1.4M Non-Dilutive Funding for Breakthrough Eye Pain Treatment - StockTitan
Neuropathic Ocular Pain Market Is Booming Worldwide 2025-2032 | - openPR
OKYO Pharma Limited ("OKYO" or the "Company")Conversion of CLNs, cashless exercise of Warrants, and issue of equity - Marketscreener.com
OKYO Pharma (NASDAQ:OKYO) & Adaptimmune Therapeutics (NASDAQ:ADAP) Head-To-Head Review - Defense World
OKYO Pharma (NASDAQ:OKYO) Stock Price Up 1.7% – Should You Buy? - Defense World
OKYO Pharma : Results of AGM 2024 - Marketscreener.com
Contrasting Genocea Biosciences (NASDAQ:GNCA) and OKYO Pharma (NASDAQ:OKYO) - Defense World
Critical Comparison: OKYO Pharma (NASDAQ:OKYO) versus enGene (NASDAQ:ENGN) - Defense World
OKYO Pharma (NASDAQ:OKYO) Trading Down 1% – What’s Next? - Defense World
OKYO Pharma to join BTIG Ophthalmology Day By Investing.com - Investing.com Canada
OKYO Pharma to Participate at the 4th Annual BTIG Ophthalmology Conference - GlobeNewswire
OKYO Pharma to join BTIG Ophthalmology Day - Investing.com
2.27%
5.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):